Filing Analysis
Delisting Notice
Filed Apr 03, 2026
HIGH
AEON Biopharma received an additional notice of non-compliance from NYSE American on March 31, 2026, due to a stockholders' deficit of approximately $55 million. This follows a previous non-compliance notice from February 2025, with a final deadline to regain compliance by August 3, 2026.
Red Flags
- Substantial stockholders' deficit of $55 million against a $4 million requirement.
- Multiple 8-K items/notices regarding listing non-compliance (Section 1003(a)(i) and 1003(a)(ii)).
- Persistent history of net losses in three of the last four fiscal years.
- Tight deadline (August 3, 2026) to bridge a massive equity gap.
Key Facts
- Received notice of non-compliance with Section 1003(a)(ii) of the NYSE American Company Guide on March 31, 2026.
- Reported a stockholders' deficit of approximately $55 million as of December 31, 2025.
- The company has reported net losses in three of its four most recent fiscal years.
- Previously received a notice for failing Section 1003(a)(i) in February 2025.
- The NYSE American has granted a compliance plan period ending August 3, 2026.
- The stock continues to trade with a '.BC' (below compliance) indicator.
Regulation FD Disclosure
Filed Mar 30, 2026
LOW
AEON Biopharma, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 30, 2026.
Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished as Exhibit 99.1 and is not considered 'filed' under Section 18 of the Exchange Act.
Officer Departure
Filed Mar 09, 2026
HIGH
AEON Biopharma appointed John Bencich as CFO and updated the employment agreement for CAO Jennifer Sy. The filing reveals the company is currently non-compliant with NYSE American listing standards, as a portion of the new CFO's equity compensation is tied to regaining compliance.
Red Flags
- Disclosure of NYSE American listing non-compliance (implied by PSU vesting conditions).
- Expansion of the Inducement Plan by 1,000,000 shares without shareholder approval, leading to potential dilution.
- Generous 'Change in Control' severance packages (12 months salary/bonus) for both the new CFO and CAO.
Key Facts
- John Bencich appointed CFO effective March 9, 2026, and Principal Financial Officer effective April 1, 2026.
- Mr. Bencich's compensation includes a $450,000 base salary, a 40% target bonus, and 754,717 RSUs.
- The company granted 235,849 PSUs to the CFO that vest only after the company regains compliance with NYSE American continued listing standards.
- The Board added 1,000,000 shares to the 2025 Employment Inducement Incentive Award Plan without stockholder approval.
- CAO Jennifer Sy entered into a formal employment agreement with a $275,000 base salary and updated severance terms.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.